Recognizing Intimate Partner Violence

The recent tragic death of Gabby Petito has highlighted the threat of violence women may face from their partners, usually called intimate partner violence (IPV). Despite being a common problem, stigma surrounding these situations leads to an unwillingness to speak of it publicly, resulting in under-recognition of a widespread, serious problem.
Intimate partner violence is common, affecting millions of people in the United States each year. Data from CDC’s National Intimate Partner and Sexual Violence Survey (NISVS) indicate that 1 in 4 women and nearly 1 in 10 men have experienced sexual violence, physical violence, and/or stalking by an intimate partner during their lifetime. IPV often starts early in life, with many experiencing these forms of violence before the age of 18, and as early as adolescence.
IPV can result in physical injury severe enough to require hospitalization; about 35% of female IPV survivors and more than 11% of male IPV survivors experience some form of physical injury. Sadly, IPV can also result in death—in fact, this is a leading cause of fatal injury in the US, with data from crime reports suggesting that about 1 in 5 homicide victims are killed by an intimate partner.
This is particularly true for women: over half of female homicide victims in the U.S. are killed by a current or former male intimate partner. In fact, a woman is far more likely to be injured or killed by her partner than a complete stranger, and are at highest risk immediately after ending an abusive relationship. The risk is even higher if firearms are stored in the house. In addition to personal violence, perpetrators of recent mass shooting incidents in the US have disproportionately had a history of previously committing IPV.
IPV affects women of all ages, backgrounds, races, cultures, and professions. More information can be found at websites for the Centers for Disease Control (CDC) and the American College of Surgeons.

Sharmila Dissanaike contributed this information as member of the Laura Bush Institute's Scientific Council.
Sharmila Dissanaike, MD, is a University Distinguished Professor and Surgical Chairman at TTUHSC in Lubbock. She is a clinically active trauma, burn and acute care surgeon who has won over 50 awards for clinical, academic, and research excellence during her career. Dr. Dissanaike is internationally known as an advocate for the advancement and equality of women in surgery and the sciences.
Related Stories
Celebrating Veterans: TTUHSC’s General Martin Clay’s Legacy of Service and Leadership
From his initial enlistment in the Army National Guard 36 years ago to his leadership in military and civilian health care management roles, Major General Martin Clay’s career has been shaped by adaptability, mission focus and service to others.
Texas Tech University Health Sciences Center School of Nursing Named Best Accelerated Bachelor of Science in Nursing Program in Texas
The TTUHSC School of Nursing Accelerated Bachelor of Science in Nursing (BSN) program has been ranked the No. 1 accelerated nursing program in Texas by RegisteredNursing.org.
TTUHSC Names New Regional Dean for the School of Nursing
Louise Rice, DNP, RN, has been named regional dean of the TTUHSC School of Nursing on the Amarillo campus.
Recent Stories
Abid Brings Hematology Expertise to TTUHSC Oncology Team
Muhammad Bilal Abid, M.D., has joined the TTUHSC School of Medicine oncology team as an associate professor of internal medicine and medical director of TTUHSC’s Blood and Marrow Transplantation & Cellular Therapy Program.
Research Team Studies Cardiovascular Disease Risk in Homeless Population
A team of student researchers from TTUHSC and TTU evaluated differences in CVD risk between men and women experiencing poverty and homelessness in West Texas, a medically underserved region within the TTUHSC service area.
Clinical Trials Provide Access to Latest Cancer Interventions
Beginning in 2008, TTUHSC, through the School of Medicine Pediatric Cancer Research Center in 2025, has conducted multiple phase 1 oncology clinical trials for pediatric and adult cancer patients. These trials will pave new ground for patients now and in the future.
